-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although the COVID-19 outbreak is far from contained, it has not stopped the continuation of R&D activities in the biopharmaceutical industry
.
According to data from Evaluate Pharma, a well-known pharmaceutical market research organization, a number of R&D projects will become the focus of attention in 2022
0 1.
The most important listed drugs
10 potential blockbuster drugs are lined up for approval in 2022
.
On June 7, 2021, after Biogen's new anti-beta amyloid drug Aduhelm (aducanumab) for the treatment of patients with early Alzheimer's disease (AD) was approved by the U.
In addition, Tirzepatide, a dual-target GLP-1/GIP agonist for type 2 diabetes developed by Eli Lilly, tezepelumab, a thymic stromal lymphopoietin (TSLP) monoclonal antibody developed by AstraZeneca/Amgen for the treatment of asthma, and Alnylam’s Treatment of hereditary transthyretin amyloidosis (hATTR) RNAi therapy Vutrisiran, Johnson & Johnson's B cell maturation antigen (BCMA) targeted chimeric antigen receptor T cell (CAR-T) therapy Cilta-cel, these projects are also is the focus of the industry
.
Meanwhile, projects developed by smaller companies like Mirati and Reata are particularly vulnerable to delays in regulatory scrutiny
.
The small molecule Nrf2 activator bardoxolone developed by Mirati for the treatment of chronic kidney disease (CKD) caused by Alport syndrome has a Prescription Drug User Fee Act (PDUFA) date of February 25, 2022
0 2.
The most valuable R&D project
Among the most valuable R&D projects, many projects still attract high valuations for projects in the early stages of clinical trials, although some projects have not yet released verifiable pivotal trial data
.
Lirentelimab (AK002), developed by Allakos, is a monoclonal antibody targeting sialic acid-binding immunoglobulin-like lectin 8 (SIGLEC-8) for the treatment of eosinophil and mast cell-related diseases
.
The drug topped the TOP10 list of the most valuable R&D projects with a net present value (NPV) of $6.
